Investigating genetic changes in aggressive lymphomas
BAF complex deregulation in lymphoma
This study is looking at two types of aggressive blood cancer, Burkitt lymphoma and diffuse large B-cell lymphoma, to find out how certain gene changes might help us create better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10896447 on NIH RePORTER |
What this research studies
This research focuses on Burkitt lymphoma and diffuse large B-cell lymphoma, two aggressive types of blood cancer. It aims to understand the genetic mutations that occur in these cancers, particularly in the ARID1A and SMARCA4 genes, which are involved in regulating gene expression. By analyzing these mutations, the research seeks to identify potential targeted therapies that could improve treatment outcomes for patients. The approach includes detailed functional analyses of these genetic alterations to develop more effective treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Burkitt lymphoma or diffuse large B-cell lymphoma, particularly those with specific genetic mutations.
Not a fit: Patients with other types of lymphomas or those who do not have the genetic mutations being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates and reduce treatment-related toxicity for patients with aggressive lymphomas.
How similar studies have performed: Previous research has shown promise in targeting genetic mutations in other cancers, suggesting that this approach could be effective for lymphomas as well.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Green, Michael Richard — University of Tx Md Anderson Can Ctr
- Study coordinator: Green, Michael Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.